Drug Profile
Research programme: retinal dystrophy therapies - Biogen
Alternative Names: 3 licensed IRD Programmes - Biogen; NSR-CNTF; NSR-OPN4; NSR-RHOLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Unknown
- Developer Biogen
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinal dystrophies